{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:27:37Z","timestamp":1787840857534,"version":"build-2784847793"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study examined the effect of hepatic arterial infusion chemotherapy (HAIC) plus programmed death 1 inhibitors (HAICPs) in patients with unresected colorectal cancer liver metastases (UCRLM) with and without KRAS mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We retrospectively collected data from patients with UCRLM, who received HAIC with HAICP or HAIC alone (oxaliplatin plus fluorouracil), including information on KRAS status (mutated, MUT; wild-type, WT) from a multicenter institutional database. Propensity score matching (PSM) was performed. The associations of KRAS status, treatment, and clinicopathological features with outcomes were determined. Confounding factors were adjusted using the Cox proportional hazard model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 668 patients (414 KRAS-WT, 254 MUT) were followed for a median of 4.6 years post-HAIC. Fifty-five percent received HAICP. Before PSM, patients in the HAICP group exhibited a significantly higher CEA level (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.014), more tumor nodules (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.012), lower clinical risk score (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009), and fewer extrahepatic metastases (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.017). After PSM analysis, 260 pairs of patients were established. The 5-year progression-free survival (PFS) for patients treated with HAICP versus HAIC was 36% and 31%, respectively (hazard ratio, 0.64; 95% CI, 0.48-0.85;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.008). The 5-year overall survival (OS) for patients treated with HAICP versus HAIC was 72% and 64%, respectively (hazard ratio, 0.44; 95% CI, 0.32-0.63;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001). In KRAS-WT tumors, the 5-year survival was 79% and 61% for patients treated with HAICP versus HAIC (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), respectively. In KRAS-MUT tumors, the 5-year survival was 68% and 52% for patients treated with HAICP versus HAIC (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001), respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The combined application of HAICP is an effective regimen for treating patients with UCRLM. HAICP shows superior survival independent of KRAS mutation. In addition, HAICP ameliorates the poor survival observed among KRAS-MUT UCRLM cases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1869_23","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T15:03:57Z","timestamp":1756998237000},"page":"818-826","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Combination of hepatic artery infusion chemotherapy and PD1 immune checkpoint inhibitor improve survival in patients with KRAS-mutated unresectable colorectal liver metastases: A propensity score matching study"],"prefix":"10.4103","volume":"21","author":[{"given":"Hao","family":"Hu","sequence":"first","affiliation":[{"name":"Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China"},{"name":"Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China"},{"name":"Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulei","family":"Gao","sequence":"additional","affiliation":[{"name":"Affiliated Jiangyin Hospital of Nantong University, Nantong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maohuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachang","family":"Chi","sequence":"additional","affiliation":[{"name":"Department of Interventional Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhe","family":"Guo","sequence":"additional","affiliation":[{"name":"Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China"},{"name":"Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"R1-20250905","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"R2-20250905","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/annonc\/mdt591","article-title":"Metastatic pattern in colorectal cancer is strongly influenced by histological subtype","volume":"25","author":"Hugen","year":"2014","journal-title":"Ann Oncol"},{"key":"R3-20250905","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(97)03358-8","article-title":"Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer, international organization for cancer chronotherapy","volume":"350","author":"L\u00e9vi","year":"1997","journal-title":"Lancet"},{"key":"R4-20250905","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1023\/A:1008347829017","article-title":"Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery","volume":"10","author":"Giacchetti","year":"1999","journal-title":"Ann Oncol"},{"key":"R5-20250905","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1634\/theoncologist.2012-0121","article-title":"The oncosurgery approach to managing liver metastases from colorectal cancer:A multidisciplinary international consensus","volume":"17","author":"Adam","year":"2012","journal-title":"Oncologist"},{"key":"R6-20250905","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.ejca.2011.06.037","article-title":"Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer","volume":"47","author":"Bouchahda","year":"2011","journal-title":"Eur J Cancer"},{"key":"R7-20250905","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.2005.05.120","article-title":"Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases:A trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer","volume":"23","author":"Ducreux","year":"2005","journal-title":"J Clin Oncol"},{"key":"R8-20250905","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","article-title":"Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma","volume":"27","author":"Kemeny","year":"2009","journal-title":"J Clin Oncol"},{"key":"R9-20250905","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/SLA.0b013e3181d35983","article-title":"Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases","volume":"251","author":"Go\u00e9r\u00e9","year":"2010","journal-title":"Ann Surg"},{"key":"R10-20250905","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2020.07.022","article-title":"Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases","volume":"138","author":"Boil\u00e8ve","year":"2020","journal-title":"Eur J Cancer"},{"key":"R11-20250905","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/SLA.0000000000003248","article-title":"Adjuvant hepatic artery infusion chemotherapy is associated with improved survival regardless of KRAS mutation status in patients with resected colorectal liver metastases:A retrospective analysis of 674 patients","volume":"272","author":"Gholami","year":"2020","journal-title":"Ann Surg"},{"key":"R12-20250905","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2):A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"R13-20250905","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3):A multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol"},{"key":"R14-20250905","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-20250905","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"R16-20250905","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1001\/jamaoncol.2020.0910","article-title":"Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer:The Canadian cancer trials group CO.26 study","volume":"6","author":"Chen","year":"2020","journal-title":"JAMA Oncol"},{"key":"R17-20250905","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/imm.13785","article-title":"A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer:Multi-pathway combination therapy with PD-1\/PD-L1 inhibitors","volume":"173","author":"Cai","year":"2024","journal-title":"Immunology"},{"key":"R18-20250905","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1053\/j.gastro.2023.04.029","article-title":"Molecular profiling provides clinical insights into targeted and immunotherapies as well as colorectal cancer prognosis","volume":"165","author":"Guo","year":"2023","journal-title":"Gastroenterology"},{"key":"R19-20250905","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.ccell.2023.04.011","article-title":"Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer","volume":"41","author":"Li","year":"2023","journal-title":"Cancer Cell"},{"key":"R20-20250905","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/SLA.0000000000002319","article-title":"RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases","volume":"269","author":"Brudvik","year":"2019","journal-title":"Ann Surg"},{"key":"R21-20250905","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/bjs\/znab086","article-title":"Contour prognostic model for predicting survival after resection of colorectal liver metastases:Development and multicentre validation study using largest diameter and number of metastases with RAS mutation status","volume":"108","author":"Kawaguchi","year":"2021","journal-title":"Br J Surg"},{"key":"R22-20250905","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1245\/s10434-020-08862-3","article-title":"Association of RAS mutation location and oncologic outcomes after resection of colorectal liver metastases","volume":"28","author":"Saadat","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R23-20250905","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/bjs.9870","article-title":"Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases","volume":"102","author":"Brudvik","year":"2015","journal-title":"Br J Surg"},{"key":"R24-20250905","doi-asserted-by":"crossref","DOI":"10.4103\/jcrt.jcrt_392_23","article-title":"Disease characteristics and prognostic factors of colorectal cancer patients with bone metastasis:A real-world data from Turkey","author":"Karabulut","year":"2024","journal-title":"J Cancer Res Ther"},{"key":"R25-20250905","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2008.19.9273","article-title":"Patients with initially unresectable colorectal liver metastases:Is there a possibility of cure?","volume":"27","author":"Adam","year":"2009","journal-title":"J Clin Oncol"},{"key":"R26-20250905","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1002\/cncr.28954","article-title":"KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases","volume":"120","author":"Kemeny","year":"2014","journal-title":"Cancer"},{"key":"R27-20250905","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.critrevonc.2015.12.015","article-title":"Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients?A systematic review and meta-analysis","volume":"99","author":"Passiglia","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"R28-20250905","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/SLA.0000000000005315","article-title":"Genomic stratification of resectable colorectal liver metastasis patients and implications for adjuvant therapy and survival","volume":"275","author":"Ecker","year":"2022","journal-title":"Ann Surg"},{"key":"R29-20250905","doi-asserted-by":"crossref","first-page":"e474","DOI":"10.1097\/SLA.0000000000004613","article-title":"Distinct genomic profiles are associated with conversion to resection and survival in patients with initially unresectable colorectal liver metastases treated with systemic and hepatic artery chemotherapy","volume":"276","author":"Datta","year":"2022","journal-title":"Ann Surg"},{"key":"R30-20250905","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2022.02.013","article-title":"Immune phenotypic linkage between colorectal cancer and liver metastasis","volume":"40","author":"Liu","year":"2022","journal-title":"Cancer Cell"},{"key":"R31-20250905","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4103\/jcrt.jcrt_1697_22","article-title":"Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma:A case report and literature review","volume":"19","author":"Zhang","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"R32-20250905","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer:Rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R33-20250905","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142):An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"R34-20250905","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation:A randomised, open-label, phase 3 trial","volume":"401","author":"de","year":"2023","journal-title":"Lancet"},{"key":"R35-20250905","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"R36-20250905","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers14010052","article-title":"Immune checkpoint inhibitors in mismatch repair proficient\/microsatellite stable metastatic colorectal cancer patients:Insights from the AtezoTRIBE and MAYA trials","volume":"14","author":"Germani","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R37-20250905","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.19.01340","article-title":"FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer:The randomized, open-label, phase II VOLFI study (AIO KRK0109)","volume":"37","author":"Modest","year":"2019","journal-title":"J Clin Oncol"},{"key":"R38-20250905","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamasurg.2019.1694","article-title":"Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases:A review","volume":"154","author":"Datta","year":"2019","journal-title":"JAMA Surg"},{"key":"R39-20250905","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","article-title":"Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer:Conversion to resection and long-term outcomes","volume":"261","author":"D\u02bcAngelica","year":"2015","journal-title":"Ann Surg"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1869_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:30:38Z","timestamp":1787837438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1869_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1869_23","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2023-08-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}